



Jornal de Pediatria

www.jpmed.com.br



ORIGINAL ARTICLE

Understanding the natural history of selective IgA deficiency

Q1 Nayara Maria Furquim Nasser *, Antonio Carlos Pastorino ,
Thais Costa Lima de Moura , Beni Morgenstern , Mayra de Barros Dorna ,
Ana Paula Beltran Moschione Castro

Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP), Instituto da Criança, Departamento de Pediatria, Divisão de Alergia e Imunologia, Hospital das Clínicas, São Paulo, SP, Brazil

Received 26 November 2024; accepted 17 March 2025

Available online xxx

KEYWORDS

Antibody deficiency;
Recurrent respiratory
infections;
Selective IgA
deficiency;
Pediatrics;
Allergic
manifestations

Abstract

Objective: Patients with selective IgA deficiency (SIgAD) present elevated morbidity associated with infections, allergic conditions, autoimmune disorders, and neoplasms. This study aims to characterize clinical manifestations, disease progression, and laboratory findings in a cohort of pediatric patients with SIgAD.

Methods: The study included patients with confirmed SIgAD and a clinical history of at least 5 years. Data encompassed clinical manifestations of the disease, patient outcomes, and laboratory findings, including IgA, IgG, IgM, IgE levels and complete blood count.

Results: A total of 51 patients (1.2:1 female-to-male ratio) were included, with a median age at diagnosis of 6 years. Infections were the most common clinical manifestations of SIgAD (98%), with pneumonia being the most frequent (94%), followed by sinusitis (70%). Additionally, 47 patients (92.1%) exhibited allergic manifestations, including rhinitis or asthma. Autoimmune conditions were identified in 10 patients, predominantly thyroiditis (60%), while neoplasms were observed in 3 patients. The sequence of disease onset revealed a natural progression, beginning with infectious diseases, followed significantly by allergic and autoimmune conditions. Elevated immunoglobulin levels (IgM or IgG) were observed in 25 patients, with hypergammaglobulinemia significantly associated with autoimmune conditions or the presence of autoantibodies ($p < 0.05$).

Conclusions: SIgAD is a clinically significant condition. Understanding its natural history deepens our knowledge of the disease and helps early detection and diagnosis of comorbidities that may arise at various stages of a patient's life. Monitoring other immunoglobulin levels may offer potential biomarkers for predicting autoimmune conditions; however, larger studies are needed to validate these biomarkers.

Institution affiliated with this work: Allergy and Immunology Division, Pediatric Department, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (HC-FMUSP), São Paulo, SP, Brazil.

* Corresponding author.

E-mail: nayara.nasser@hc.fm.usp.br (N.M. Nasser).

<https://doi.org/10.1016/j.jpmed.2025.03.002>

0021-7557/© 2025 The Author(s). Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Please cite this article in press as: N.M. Nasser, A.C. Pastorino, T.C. de Moura et al., Understanding the natural history of selective IgA deficiency, *Jornal de Pediatria* (2025), <https://doi.org/10.1016/j.jpmed.2025.03.002>

© 2025 The Author(s). Published by Elsevier Editora Ltda. on behalf of Sociedade Brasileira de Pediatria. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1 Introduction

2 The IgA present in mucosal surfaces constitutes the first line
3 of defense against microorganisms through mechanisms that
4 include direct pathogen neutralization, intracellular neu-
5 tralization of viruses during transepithelial transport, and
6 immune cell activation mediated by receptors.¹ It also
7 reduces or prevents the penetration of various allergens into
8 the mucosal membranes where it is found.²

9 Selective immunoglobulin A deficiency (SIgAD) is the most
10 prevalent inborn errors of immunity (IEI).³ SIgAD is defined
11 by serum IgA levels below 0.07 g/L (or 7 mg/dL), with normal
12 serum levels of IgG and IgM, in patients over 4 years of age,
13 after excluding other causes of hypogammaglobulinemia.^{4,5}
14 Its incidence varies depending on the ethnicity studied, esti-
15 mated at 1:600 in the general population and 1:965 in Bra-
16 zil.⁶ It is possible that SIgAD is underestimated due to the
17 lack of routine screening protocols and because most car-
18 riers are asymptomatic.⁷ Symptomatic patients represent
19 approximately 10–35% of all SIgAD cases.^{4,8}

20 In symptomatic individuals, there is a predominance of
21 infectious processes, primarily affecting the respiratory and
22 gastrointestinal mucosa, accompanied by allergic conditions
23 such as asthma and rhinitis, as well as autoimmune disorders
24 and neoplasms. In pediatric populations, recurrent infections
25 represent the primary clinical manifestation, often warranting
26 immunological evaluation;⁸ however, a definitive diagnosis of
27 selective IgA deficiency (SIgAD) can only be confirmed through
28 investigations conducted after the age of four in order to
29 exclude other potential causes such as delayed immune sys-
30 tem maturation and increased environmental exposure, which
31 may account for the elevated infection rates.^{1,4}

32 Although the symptoms of SIgAD are well-documented,
33 there are few studies exploring the natural history of the dis-
34 ease and the potential for progression over the years. Our
35 goal was to describe the clinical presentations of SIgAD and
36 its progression, along with laboratory findings, in a cohort of
37 pediatric patients.

38 Methods

39 This is a prospective descriptive study with information col-
40 lected from medical records, conducted at a reference cen-
41 ter specializing in patients with inborn errors of immunity.
42 The study was approved by the Local Research Ethics Com-
43 mittee (approval number 5.051.369, 2021).

44 All patients with a confirmed diagnosis of symptomatic
45 SIgAD, from 1996 to the present, were included. IgA defi-
46 ciency was defined by the presence of serum IgA levels
47 below 0.07 g/L or 7 mg/dL, associated with normal serum
48 levels of IgG and IgM in patients older than 4 years of age,
49 after other causes of hypogammaglobulinemia had been
50 excluded. All patients were required to have at least 5 years
51 of clinical history. Patients with other inborn errors of immu-
52 nity, genetic syndromes, or secondary IgA deficiency

53 resulting from pharmacological treatments were excluded
54 from the study.

55 The data extracted from the medical records comprised
56 epidemiological information, (including date of birth, sex,
57 and age at onset of symptoms), infection profile (type of
58 infection, onset, and frequency of episodes), diagnosis of
59 allergies (compatible history of asthma, allergic rhinitis,
60 atopic dermatitis, and food allergy), autoimmune diseases
61 (diagnosis confirmed by a rheumatologist), and neoplasms
62 (diagnosis confirmed by an oncologist).

63 Laboratory analyses were conducted using data from
64 medical records, and all tests were performed at the refer-
65 ence center's laboratory. Immunoglobulin A, M, and G levels
66 were quantified via immunoturbidimetry (mg/dL), while
67 Immunoglobulin E levels were measured using electrochemi-
68 luminescence (IU/mL). Hematological parameters including
69 red blood cell count, hemoglobin concentration, leukocyte
70 count, neutrophils, and lymphocytes were assessed. Autoan-
71 tibodies were evaluated, including Antinuclear Antibodies
72 (ANA), Anti-Peroxidase Antibodies (Anti-TPO), Anti-Thyro-
73 globulin Antibodies (Anti-Tg), Rheumatoid Factor (RF), Anti-
74 Neutrophil Cytoplasmic Antibodies (ANCA), Anti-SSA/RO,
75 Anti-SSB/LA, and Anti-Native DNA were evaluated if ANA
76 was positive or if there were suspicious clinical features.
77 Detection methods included indirect immunofluorescence
78 for ANA and ANCA, chemiluminescent immunoassay for Anti-
79 TPO and Anti-Tg (IU/mL), immunoturbidimetry for RF, and
80 ELISA for Anti-SSA/RO, Anti-SSB/LA, and Anti-Native DNA.

81 For the description of laboratory results, including hema-
82 tology and immunoglobulin quantifications throughout the
83 follow-up period, the following methodology was used: tests
84 performed during active infectious episodes or hospitaliza-
85 tions were excluded. Subsequently, only tests with an inter-
86 val of 1 year between each collection were selected for
87 analysis. The following standard was set for classifications of
88 anemia, leukopenia, leukocytosis, neutropenia, neutro-
89 philia, lymphocytosis, lymphopenia, increased or decreased
90 IgG, IgM: the majority (> 50%) of the tests analyzed were
91 outside the normal range described in the reference values
92 for each test according to the patient's age.

93 The progression of clinical manifestations was described
94 based on the age of onset of each listed condition: infec-
95 tions, allergic diseases, autoimmunity, and neoplasms. The
96 Kruskal-Wallis test, followed by the Dwass-Steel-Critchlow-
97 Flinger post-hoc test, was employed to determine if there
98 were significant differences in the time of onset among the
99 various manifestations. A *p*-value of <0.05 was considered
100 statistically significant. Additionally, a Venn diagram was
101 used to evaluate the overlap of clinical manifestations
102 among the patients.

103 The correlation between laboratory values and clinical
104 manifestations was evaluated using the Chi-Square and Fisher's
105 exact tests. The levels of IgG, IgM, and IgE were ana-
106 lyzed in relation to the presence or absence of cardinal
107 symptoms in patients with SIgAD, including infections, aller-
108 gies, autoimmune diseases, and neoplasms.




Figure 1 Screening design. Flowchart of patient selection. 1—Urinary tract infection; 2—Type 1 diabetes mellitus; 3—Idiopathic thrombocytopenic purpura; 4—Juvenile idiopathic arthritis; 5—Systemic lupus erythematosus.

Results

Of the 79 patients referred to the investigation of IEI with an initial presumptive diagnosis of SIgAD, 51 met the inclusion criteria (Figure 1). The 51 patients (1.2F:1 M) were followed for an average of 10 years with a standard deviation of ± 2.8 years (ranging from 5 to 16 years). The median age at the time of SIgAD diagnosis was 6 years (ranging from 4 to 13 years), and the median age at the onset of the first symptom was 1 year. Consanguinity was reported in two families, and only one of the cases was associated with other instances of SIgAD. A family history of SIgAD was observed in eight patients.

The most frequent clinical manifestations were infectious, with a notably early onset, particularly involving respiratory infections (Table 1). More than half of the patients (66%) experienced involvement of multiple infectious sites during the follow-up period. Respiratory allergies, especially rhinitis, were highly prevalent (97.8%), with asthma occurring in 31 patients (67%). An association between respiratory allergies and airway infections was observed in 45 patients (88.2%).

Autoimmune diseases were concomitant in two of the eight affected patients. The presence of autoantibodies without clinical manifestations was detected in 31 patients (60.7%), beginning at 3 years of age, with a median age of antibody detection at 9 (ranging from 3 to 15 years). The most common autoantibodies were antinuclear antibodies (21 patients, 67.7%), followed by antithyroglobulin and antithyroid peroxidase antibodies, each being detected in 12 patients (38.7%).

Over a period of at least five years of disease history, the ages of onset for the cardinal symptoms showed statistically significant differences, with infections being the earliest clinical manifestations of SIgAD compared to allergies and autoimmune conditions (p < 0.05). It was shown that the majority of patients had more than one associated clinical manifestation (Figure 2). Allergies and infections were the most frequently observed manifestations in this patient group. None of the patients presented with autoimmune diseases in isolation. Among the three patients with neoplasms,

two also presented autoimmunity, infections, and allergies, while the third patient only experienced infections and allergies.

During the follow-up, changes in diagnosis were observed: nine patients progressed to partial IgA deficiency at an average age of 10.6 years (ranging from 6 to 14 years), of which four normalized IgA levels over the years, with an average age of 13 years (ranging from 9 to 15 years). Two patients progressed to Common Variable Immunodeficiency (CVID), one at 12 years of age and the other at 18 years.

Laboratory tests were collected throughout the follow-up period. On average, patients underwent 9 test collections (ranging from 3 to 15 tests per patient, with a median of 9). Regarding blood counts, four patients (7.8%) had anemia, four (7.8%) had mild leukopenia, (3280–4600 cells/mm³) and none had lymphopenia.

Considering the immunoglobulin levels (IgG, IgM), 25 patients (49%) presented values above the 97.5th percentile, indicating hypergammaglobulinemia. Among these patients, 14 (56%) showed elevated values on more than 70% of their samples. IgG levels were above the age-specific reference values in 20 of the 25 patients, while IgM levels were elevated in 5 of the 25 patients.

There was a correlation between elevated levels of IgG or IgM and a higher prevalence of autoimmune diseases and autoantibodies without clinical manifestations (p < 0.05). However, there was no significant correlation between these elevated levels and the presence of infections or allergies (Figure 3).

On average, 4.8 (ranging from 2 to 10) IgE measurements were taken per patient during the follow-up. Of the 51 patients, 20 presented IgE levels above the age-specific reference values. However, there was no significant clinical correlation between elevated IgE levels and the presence or severity of allergies.

Discussion

SIgAD is the most prevalent IEI, with prevalence rates among blood donors varying from 1:163 in Spain and 1:143 in the Arabian Peninsula to 1:4100 in China and 1:18,550 in Japan, suggesting a lower prevalence among Asian populations.⁹ Few studies have examined the long-term outcomes of patients with SIgAD, making our case series relevant for specialists, pediatricians, and clinicians who may encounter asymptomatic or oligosymptomatic patients with routine tests showing low IgA levels.¹⁰ Due to the characteristics of this cohort, the data were not compared to the normal population. However, the high number of infectious processes—more than three per patient, including pneumonia—characterizes this population as one warranting immunological investigation.

The patients included in this study showed a slight predominance of females, differing from the literature, which typically shows a male predominance, without any specific reason, probably related to the sample size.⁸ The presence of a family history of SIgAD varies across studies, and cultural aspects must be considered. In countries with a high number of consanguineous marriages, the rates of multiple cases within one family are higher than in other countries. In

Table 1 Clinical symptoms.

Clinical features							
Symptoms related to:	N (%)	Median age at onset (years) (min–max)	Diseases	N (%)			
Infection	50 (98.0)	1.0 (0.1–6)	Pneumonia	47 (94.0)			
			Sinusitis	35 (75.0)			
			Otitis	27 (54.0)			
			Gastrointestinal	27 (54.0)			
			Tonsillitis	22 (44.0)			
			UTI ^a	13 (26.0)			
			Impetigos	4 (8.0)			
			Parotitis	2 (4.)			
			Viral meningitis	2 (4.0)			
			Ostomastoiditis	1 (2.0)			
			Sepsis	1 (2.0)			
			Osteomyelitis	1 (2.0)			
			Allergies	47 (92.1)	5.0 (0.1–15)	Rhinitis	46 (97.8)
Asthma	30 (63.8)						
Atopic dermatitis	9 (19.1)						
Food allergy	3 (6.3)						
Tideoiditis	6 (60.0)						
DM1 ^b	1 (10.0)						
Rheumatic fever	1 (10.0)						
Autoimmunities	10 (19.6)	8.0 (4.0–13)	Celiac disease	1 (10.0)			
			ITP ^c	1 (10.0)			
			JIA ^d	1 (10.0)			
			Vitiligo	1 (10.0)			
			Grave' disease	1 (10.0)			
			SLE ^e	1 (10.0)			
			Langerhans histiocytosis	2 (66.6)			
			Hodgkin's lymphoma	1 (33.3)			
			Neoplasms	3 (5.8)	9 (1.6–15)		

Clinical features of confirmed of SIgAD.

^a Urinary tract infection.

^b Type 1 diabetes mellitus.

^c Idiopathic thrombocytopenic purpura.

^d Juvenile idiopathic arthritis.

^e Systematic lupus erythematosus.





Figure 2 Overlapping disease and follow up. (A) Venn diagram of overlapping disease in patients with SIgAD. (B) Age-dependent disease variation in patients with IgA deficiency.

207 our study, the authors observed few consanguineous families
208 and a low rate of family history.^{11,12}

209 The association between IgA deficiency and infections is
210 due to the lack of mucosal defense mechanisms, which are

211 not fully compensated for by other immunoglobulins. IgA is
212 the main class of immunoglobulin on mucosal surfaces and is
213 highly effective in containing pathogens without significant
214 tissue damage due to its protective characteristics (local



VARIABLE	Total (N=51)	Hypergamma (N=25)	No Hypergamma (N=26)	p
	N (%)	N (%)	N (%)	
Infections	50 (98)	25 (100)	25 (96.1)	0.317
Allergies	47 (92.1)	24 (96)	23 (88.4)	0.322
Autoimmunities	10 (19.6)	8 (32)	2 (7.6)	0.038
Presence of Auto – Ac without clinical manifestations	31 (60.8)	19 (61.3)	12 (38.7)	0.029
Neoplasms	3 (5.8)	2 (8)	1 (3.8)	0.529

Figure 3 Immunoglobulins levels: correlations between hypergammaglobulinemia and clinical features in SIgAD patients (A and B).

215 non-inflammatory defense and absence of complement activation). IgA functions by blocking the adhesion and aggregation of microorganisms and may assist in the intracellular neutralization of pathogens.¹³

219 Upper respiratory tract infections are a common complaint in pediatrics for multiple reasons and some of these children may have SIgAD, a diagnosis that needs to be considered. In this study, infections were the most frequent manifestations, with upper respiratory tract infections being particularly prominent. In children, recurrent infections are the primary manifestations that may lead to an immunological investigation.¹⁴ Respiratory and gastrointestinal tract infections are the most common clinical manifestations in children with symptomatic SIgAD, occurring in 40–90% of cases.^{8,13} Pneumonia was the most frequent complaint, and while IgA is more crucial in the upper airway, this study, conducted in a tertiary hospital, may have a bias toward more severe patients. However, the literature describes phenotypes of IgA deficiency where some patients may have more severe manifestations or may be associated with other deficiencies such as IgG2 and/or IgG3 subclasses. More severe infectious manifestations such as otomastoiditis, sepsis, and osteomyelitis were described as isolated events in this study and in literature reports.^{8,11,13,14}

239 One limitation of this study was the use of medical records as a data source, which restricts the detail and quantification of the progression of infectious processes. Nevertheless, the scarcity of studies evaluating the natural history of SIgAD underscores the importance of these findings.

245 In SIgAD, although the underlying pathogenetic mechanism is not yet fully elucidated, the reduction of serum and secretory IgA can lead to colonization and penetration by pathogenic bacteria, and facilitate the passage of aeroallergens and food antigens, predisposing patients with SIgAD to a higher risk of developing allergies. The absence of IgA in mucosal surfaces may contribute to increased permeability and greater exposure to allergens, facilitating the development of allergies.^{7,15}

254 In this study, allergic diseases significantly affected patients with SIgAD and had an early onset, around 5 years of age. The authors observed high rates of allergic rhinitis and asthma, with less pronounced rates of atopic dermatitis and food allergies, a finding consistent with previous reports.^{16,17} Allergic manifestations are possible in patients

with various primary immunodeficiencies (PIDs), but a study by the World Allergy Organization (WAO) showed that SIgAD is the second most prevalent PID associated with allergies.¹⁸ Patients with severe asthma may be a key group for SIgAD screening, with a local study detecting a prevalence of 3.8% among patients with severe asthma.^{7,15,19}

Some studies demonstrate that SIgAD leads to the activation of compensatory mechanisms, such as the increase in secretory IgM.²⁰ Another study suggests that systemic IgG and secretory IgA work together in different body compartments to limit systemic pro-inflammatory pathways. IgA mediates a homeostatic dialogue between the systemic immune compartment, although this mechanism is not yet fully understood.²¹ Our data suggests that patients with SIgAD exhibited elevated levels of IgG and IgM, along with a higher prevalence of autoimmunities and autoantibodies without clinical manifestation.

Autoimmune diseases were the third most prevalent group of conditions in our study, with significant variability in clinical presentations and with few associations between diseases. The causes of these associations were not clear, and the mechanisms may be multiple and non-exclusive. One hypothesis suggests that certain human leukocyte antigen (HLA) genes in the MHC locus on chromosome 6 may favor the development of SIgAD and autoimmune diseases, or that an unknown genetic defect could explain the association between SIgAD and autoimmunity, characterizing this phenotype of SIgAD as a monogenic disease.^{22,23}

A thorough review by Odineal & Gershwin suggests that abnormalities in B cells, T cells, or cytokines in SIgAD patients may contribute to autoimmune susceptibility. The lack of IgA might contribute to a state of persistent local and systemic inflammation. Persistent inflammation leads to several negative health consequences, partly through the release of interferon IFN- γ , type I IFNs, interleukin IL-1 β , IL-12, IL-17, and tumor necrosis factor- α , and may predispose immune cells to sensitize to autoantigens. Additionally, IgA interacts with cell receptors such as Fc α RI to negatively regulate immune pathways, which can, in turn, propagate inflammation.^{1,9,24}

Although occurring later, autoimmune diseases are notably present in patients with IgA deficiency, making them a significant manifestation to monitor and manage in the long term.²⁴ A study conducted on Turkish children with SIgAD found autoimmune manifestations in 17.3% of cases, a high

percentage considering the age of this population (mean age of the study was 9.9 years \pm 3.9).^{24,25} In our study, the median age of onset for autoimmune diseases was eight years, which is considered early for most autoimmune diseases diagnosed. In pediatrics, most autoimmune diseases typically occur during puberty,²⁶ particularly around 16 years of age. Koskinen S (1996), after long-term follow-up of patients with SIgAD, observed the onset of autoimmune diseases at an average age of 31 years. This finding highlights the need for long-term follow-up of patients with SIgAD to detect autoimmune manifestations and enable early diagnosis of these conditions.^{1,27}

It is worth noting the high rate of autoantibodies among patients, as observed by Sarmiento and Gulez et al. In the latter study, the presence of autoantibodies was significantly higher in children with SIgAD compared to healthy control children. Although frequently, the detection of autoantibodies cannot predict whether a patient with SIgAD will develop an autoimmune disease.²⁸

The follow-up of patients with SIgAD presents several challenges: they may exhibit extremely variable phenotypes, ranging from entirely asymptomatic to mild or severe infections, allergies, and autoimmune diseases.¹¹ In this study, during at least five years of follow-up after the diagnosis of SIgAD, it was observed with statistical significance that the ages of onset for infections, allergies, and autoimmune diseases were variable. Yazdani et al. (2015) classified SIgAD into different phenotypes and severe and allergic ones tend to manifest in childhood, while mild infections and autoimmune phenotypes are more commonly diagnosed in midlife.¹¹ Considering the progression of our patients with SIgAD, most of whom exhibited overlapping manifestations, it becomes evident that classifying them into a single phenotype is challenging. Most of our patients showed high rates of association between infections and allergies. Nearly one-fifth presented an association among all three major disease groups, revealing the complexity of SIgAD and the need for multidisciplinary and long-term follow-up.

Plebani et al. demonstrated that patients with SIgAD showed higher serum concentrations of IgG, IgM, and secretory IgM compared to controls.²⁹ Secretory IgA appears to support the intestinal barrier in maintaining homeostatic levels of interaction between commensal microbes and the systemic immune system. In the absence of secretory IgA, the barrier's function is compromised, resulting in increased systemic exposure to commensal microorganisms. This can lead to aberrant humoral and systemic responses to these microbes.³⁰

SIgAD in children is a relevant and common condition. Understanding the natural history of patients with SIgAD deepens the comprehension of the disease and helps early awareness and diagnosis of comorbidities that may arise at different stages of the patient's life. Regular monitoring of IgA levels is necessary, with attention to the potential for normalization; however, ongoing follow-up is crucial due to the risk of progression to other immunodeficiencies, the development of autoimmune diseases, and vigilance for neoplasms. Additionally, monitoring other immunoglobulins may aid in identifying potential biomarkers for autoimmunity, though further studies are needed to validate these biomarkers.

Funding

This study has not received any specific grants from funding agencies in the public, commercial, or non-profit sectors. NMFN received a grant from CAPES (number 88887.806719/2023-00).

Conflicts of interest

The authors declare no conflicts of interest.

Editor

D. Solé

References

- Jacob CM, Pastorino AC, Fahl K, Carneiro-Sampaio M, Monteiro RC. Autoimmunity in IgA deficiency: revisiting the role of IgA as a silent housekeeper. *J Clin Immunol*. 2008;28:556–61.
- de Sousa-Pereira P, Woof JM. IgA: structure, function, and developability. *Antibodies (Basel)*. 2019;8:57.
- Modell V, Orange JS, Quinn J, Modell F. Global report on primary immunodeficiencies: 2018 update from the Jeffrey Modell Centers Network on disease classification, regional trends, treatment modalities, and physician reported outcomes. *Immunol Res*. 2018;66:367–80.
- Yel L. Selective IgA deficiency. *J Clin Immunol*. 2010;30:10–6.
- Conley ME, Notarangelo LD, Etzioni A. Diagnostic criteria for primary immunodeficiencies. Representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). *Clin Immunol*. 1999;93:190–7.
- Carneiro-Sampaio MM, Carbonare SB, Rozentraub RB, de Araújo MN, Riberiro MA, Porto MH. Frequency of selective IgA deficiency among Brazilian blood donors and healthy pregnant women. *Allergol Immunopathol (Madr)*. 1989;17:213–6.
- Cinicola BL, Pulvirenti F, Capponi M, Bonetti M, Brindisi G, Gori A, et al. Selective IgA deficiency and allergy: a fresh look to an old story. *Medicina (Kaunas)*. 2022;58:129.
- Moschese V, Chini L, Graziani S, Sgrulletti M, Gallo V, Di Matteo G, et al. Follow-up and outcome of symptomatic partial or absolute IgA deficiency in children. *Eur J Pediatr*. 2019;178:51–60.
- Singh K, Chang C, Gershwin ME. IgA deficiency and autoimmunity. *Autoimmun Rev*. 2014;13:163–77.
- Corsello A, Milani GP, Picca M, Buzzetti R, Carrozzo R, Gambino M, et al. Recurrent upper respiratory tract infections in early childhood: a newly defined clinical condition. *Ital J Pediatr*. 2024;50:30.
- Yazdani R, Latif A, Tabassomi F, Abolhassani H, Azizi G, Rezaei N, et al. Clinical phenotype classification for selective immunoglobulin A deficiency. *Expert Rev Clin Immunol*. 2015;11:1245–54.
- Santos S, Kok F, Weller M, de Paiva FR, Otto PA. Inbreeding levels in Northeast Brazil: strategies for the prospecting of new genetic disorders. *Genet Mol Biol*. 2010;33:220–3.
- Ludvigsson JF, Neovius M, Hammarstrom L. Risk of infections among 2100 individuals with IgA deficiency: a nationwide cohort study. *J Clin Immunol*. 2016;36:134–40.
- Swain S, Selmi C, Gershwin ME, Teuber SS. The clinical implications of selective IgA deficiency. *J Transl Autoimmun*. 2019;2:100025.
- Morawska I, Kurkowska S, Bębnowska D, Hryniewicz R, Becht R, Michalski A, et al. The epidemiology and clinical

- 421 presentations of atopic diseases in selective IgA deficiency. *J* 450
 422 *Clin Med.* 2021;10:3809. 451
- 423 16. Aghamohammadi A, Cheraghi T, Gharagozlou M, Movahedi M, 452
 424 Rezaei N, Yeganeh M, et al. IgA deficiency: correlation between 453
 425 clinical and immunological phenotypes. *J Clin Immunol.* 454
 426 2009;29:130–6. 455
- 427 17. Lougaris V, Sorlini A, Monfredini C, Ingrassiotta G, Caravaggio A, 456
 428 Lorenzini T, et al. Clinical and laboratory features of 184 italian 457
 429 pediatric patients affected with selective IgA deficiency 458
 430 (SIgAD): a longitudinal single-center study. *J Clin Immunol.* 459
 431 2019;39:470–5. 460
- 432 18. El-Sayed ZA, El-Ghoneimy DH, Ortega-Martell JA, Radwan N, 461
 433 Aldave JC, Al-Herz W, et al. Allergic manifestations of inborn 462
 434 errors of immunity and their impact on the diagnosis: a world- 463
 435 wide study. *World Allergy Organ J.* 2022;15:100657. 464
- 436 19. Pastorino AC, Accioly AP, Lanzellotti R, Camargo MC, Jacob CM, 465
 437 Grumach AS. Asthma - clinical and epidemiological aspects of 466
 438 237 outpatients in a specialized pediatric unit. *J Pediatr (Rio J).* 467
 439 1998;74:49–58. 468
- 440 20. Catanzaro JR, Strauss JD, Bielecka A, Porto AF, Lobo FM, Urban 469
 441 A, et al. IgA-deficient humans exhibit gut microbiota dysbiosis 470
 442 despite secretion of compensatory IgM. *Sci Rep.* 2019;9:13574. 471
- 443 21. Fadlallah J, Sterlin D, Fieschi C, Parizot C, Dorgham K, El Kafsi 472
 444 H, et al. Synergistic convergence of microbiota-specific sys- 473
 445 temic IgG and secretory IgA. *J Allergy Clin Immunol.* 2019;143: 474
 446 1575–85. 475
- 447 22. Wang N, Shen N, Vyse TJ, Anand V, Gunnarson I, Sturfelt G, 476
 448 et al. Selective IgA deficiency in autoimmune diseases. *Mol* 477
 449 *Med.* 2011;17:1383–96. 478
23. Lovell DJ, Huang B, Chen C, Angeles-Han ST, Simon TA, Brunner 450
 451 HI. Prevalence of autoimmune diseases and other associated 452
 conditions in children and young adults with juvenile idiopathic 453
 arthritis. *RMD Open.* 2021;7:e001435. 454
24. Odineal DD, Gershwin ME. The epidemiology and clinical mani- 455
 456 festations of autoimmunity in selective IgA deficiency. *Clin Rev* 457
Allergy Immunol. 2020;58:107–33. 458
25. Erkoçoglu M, Metin A, Kaya A, Özcan C, Akan A, Civelek E, et al. 459
 460 Allergic and autoimmune disorders in families with selective IgA 461
 deficiency. *Turk J Med Sci.* 2017;47:592–8. 462
26. Calcaterra V, Nappi RE, Regalbuto C, De Silvestri A, Incardona A, 463
 464 Amariti R, et al. Gender differences at the onset of autoimmune 465
 thyroid diseases in children and adolescents. *Front Endocrinol* 466
(Lausanne). 2020;11:229. 467
27. Koskinen S. Long-term follow-up of health in blood donors with 468
 469 primary selective IgA deficiency. *J Clin Immunol.* 1996;16: 470
 165–70. 471
28. Gulez N, Karaca NE, Aksu G, Kutukculer N. Increased percen- 472
 473 tages of autoantibodies in immunoglobulin A-deficient children 474
 do not correlate with clinical manifestations. *Autoimmunity.* 475
 2009;42:74–9. 476
29. Plebani A, Mira E, Mevio E, Monafò V, Notarangelo LD, Avanzini 477
 478 A, et al. IgM and IgD concentrations in the serum and secretions 479
 of children with selective IgA deficiency. *Clin Exp Immunol.* 480
 1983;53:689–96. 481
30. Conrey PE, Denu L, O'Boyle KC, Rozich I, Green J, Maslanka J, 482
 483 et al. IgA deficiency destabilizes homeostasis toward intestinal 484
 microbes and increases systemic immune dysregulation. *Sci* 485
Immunol. 2023;8:eade2335. 486